Member Info for Scarabbeatle

Interferon beta (IFN-beta) potential applicability to COVID-19

Interferon beta is a naturally occurring protein, which orchestrates the body's antiviral responses. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility of these at-risk patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2 and MERS-CoV, have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells either prevents or greatly diminishes cell damage and viral replication, respectively. Synairgen's SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action.



SNG001 could prove to have an important role to play in outbreaks such as the current COVID-19 epidemic, particularly in respect of the population at highest risk of being severely affected by this and similar viruses.



SNG001 was identified in the WHO's Landscape analysis of therapeutics as at 17 February 2020 as the only Phase 2/Phase 3/Observational therapy delivered by the inhaled route.

This is the RNS for the start of the COPD trial. Which was set up to test sng 001 effectiveness against influenza/flu as a recognised anti viral. To be trialled over last winter. There was additional benefits from previous lab tests which I will post

24th Jul 2019 07:00

RNS Number : 5331G
Synairgen plc
24 July 2019



RNS REACH

Press release

Synairgen plc

('Synairgen' or the 'Company')



Phase II Clinical Trial Update in Patients with COPD



~ Clinical trial data to date shows impact of viruses on COPD patients



Southampton, UK - 24 July 2019: Synairgen (LSE: SNG), the respiratory drug discovery and development company, today announces an update on the Company's wholly-owned inhaled interferon beta (IFN-beta) programme, currently in a Phase II clinical trial, which is aimed at countering the adverse effects of common cold and influenza viruses in patients with chronic obstructive pulmonary disease (COPD).

The trial is progressing well in 15 centres around the UK and is scheduled to complete in the winter 2019-2020 virus season.

Prof. Tom Wilkinson, Chief Investigator for the trial, said: "COPD exacerbations caused by cold and influenza viruses represent a significant health risk, particularly in the winter virus season. Patients with COPD exacerbations are the second most likely group of patients to be hospitalised in England for unplanned events.

"With no effective broad-spectrum antiviral treatment on the market, Synairgen's inhaled IFN-beta may provide a novel approach for COPD patients, with the potential to greatly improve the patient's defences against viral infection, reduce exacerbations, increase quality of life and reduce hospitalisations."

Are they still recruiting? 14 day treatment from last patient enrollment. Fantastic opportunity for synairgen to progress.

Just shows on positive results of these trials then we could potentially be one of the first line treatment options for patients within the first 10 days of viral infection. When symptoms either disappear or continue to worsen.

If proven as an effective treatment, the bulk buying and making of IFN beta with the increased demand would surly bring the price down. The same with the single patient nebuliser. Sng is still looking strong.

I think this is part of the COPD trial. Dealing with viral infections on people with Compromised immune response.

Especially since the sars outbreak of the 2000s, and still no vaccine, over 10 years later.

Within the 1 maybe 2 day turn around for the standard swab tests which you could potentially catch the virus inbetween. 10 minute saliva test is the way forward. Just to be safe, test everyone before the flight and once landing and going through passport control.

They use interferon beta 1a, but it is injectable which causes worse side effects as need to give a high dose than sng. Sng have the patents on their nebulised version which is delivered direct to the lungs.

This article is about an antibody test, not relevant for avct

I think faron use a supplier also, but this move is turning them into a new supplier as well as selling there IV form of IFNB 1a. I took it from their RNS this morning as a positive as well.

When the results come back and if they show positive results in the three areas which are being/have been in various trials in the last few months, benefit for COPD sufferers, hospital trial and the at home trial. Then it could be the first proven treatment for c19.

A lot of news in the pipeline, been in Sng a while now, hopefully the hard work from the company will show significant results shortly. Then game on

Still synairgen are amongst the front runners to develop a fully tested and reviewed treatment for the latest identified corona virus, if shown positive results it will be used to treat people suffering the worst every flu season and should be on the list of approved treatments for any further outbreaks of mers/sars corona virus'. Plenty of positives left in this company well beyond this year.

The news has been out for 24hrs, which gives plenty of time to show all the positives this company can provide, today sp movements would give a fair reflection on yesterday's new IMO.

Not yet, give it a couple more weeks.

Just shows how far Avcata are ahead of the game for the POC test we are

Good news all round, and I expect more to come. There should be a increase in volume of trades, and an upward trend, I imagine traders will be selling into the rise as well.

I hope you don't shove a tampon in your mouth lol.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.